ANY SINGLE OR MULTIPLE MONOCLONAL ANTIBODIES, OR OTHER FC-BASED LIGANDS CAN BE USED, ONCE ENGINEERED, TO PRE-ARM THE EFFECTOR CELLS BEFORE THERAPEUTIC INJECTIONS
Former Head of Manufacturing at Mesoblast (NASDAQ: MESO). Ex- Professor at UTMD Anderson Cancer Center. Led the Cell Therapy Laboratory at UTMD and designed its facility.
Former SVP Global Clinical Development at Merck KGaA with a strong track record of drug approval (Rebif, Mavenclad). Previously Head of Scientific Affairs and Investor Relations at Serono (listing NYSE).
CEO of the Grünenthal Group (€ 1,4B Sales, 4’700 employees in 2019). Previously Company President of AstraZeneca Japan and Germany. Managed brands in immuno-oncology.
Non-executive director. Formerly Ambassador to The People’s Republic of China, to Mongolia and the DPRK (2014-2019). Previously Ambassador to France and Monaco (2011-2014).
Highly experienced drug developer with a strong track record of drug approvals
Initiator & director of the Institute for Regenerative Medicines & Biotherapy (IRMB) at Montpellier, France.